NICE allows immunotherapy treatment for small group of patients with advanced triple negative breast cancer

The National Institute for Health and Care Excellence (NICE) has now ruled that pembrolizumab (Keytruda) plus chemotherapy should be available as a treatment option for a limited group of patients…

Read Original Article: NICE allows immunotherapy treatment for small group of patients with advanced triple negative breast cancer »